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toxicity was seen between patients with SCN involvement and 
those without,irrespective of the location of the primary 
tumor.  
 
Conclusion: In esophageal cancer treated with definitive 
chemoradiation, number of affected lymph nodes is an 
important prognostic factor, while involvement of a 
supraclavicular lymph node is not. The supraclavicular lymph 
node should beconsidered a regional lymph node and treated 
with curative intend if the total number of involved lymph 
nodes is limited, irrespective of the site of the primary 
tumor. 
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Purpose or Objective: To define the role of radiation dose 
on overall survival (OS) in pancreatic adenocarcinoma (PAC) 
patients treated with adjuvant chemoradiotherapy (CRT). 
 
Material and Methods: A total of 518 patients from different 
centers, completely resected with macroscopically negative 
margins (R0-1) for PAC (T1-3; N0-1; M0) and treated with 
adjuvant CRT, were retrospectively reviewed. Patients with 
metastatic or unresectable disease at surgery, macroscopic 
residual disease (R2), treated with intraoperative 
radiotherapy (IORT), dead within 60 days of surgery and 
without a histological diagnosis of ductal carcinoma were 
excluded. Only 142 patients received adjuvant 
chemotherapy. 
 
Results: With 35 months of median follow-up, median OS was 
23.0 months after adjuvant CRT with dose ≥ 45 Gy versus 
13.0 months with dose < 45 Gy (p < 0.001); 5-year OS was 
21.9% versus 3.8%, respectively. Among prognostic factors, 
higher Ca19-9 levels (>90; p<0.001), higher tumor grade (G3-
4, p = 0.017), R1 resection (p = 0.003), higher pT stage (p = 
0.002) and positive nodes (p < 0.001) can be identified as 
negative. Multivariate analysis (HR: 0.52, 0.34-0.77; p = 
0.001) proved the positive impact of higher dose.  
 
Conclusion: A significant impact of CRT dose on OS was 
pointed out by the results of this analysis. The randomized 
trials on adjuvant CRT in PAC, in which a relatively low-dose 
of radiation (40 Gy, split course) was used, may have had 
conflicting results due to this bias.  
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Purpose or Objective: To compare long-term outcomes of 
chemoradiotherapy between young and elderly (≥70 years) 
oesophageal cancer patients treated with curative intent. 
 
Material and Methods: Oesophageal cancer patients treated 
between 1998 and 2013 in our institute with neoadjuvant 
(nCRT) or definitive (dCRT) chemoradiotherapy were 
retrospectively analysed. nCRT consisted of 36-50Gy with 
concurrent 5-fluorouracil/cisplatin or 41.4Gy with concurrent 
carboplatin/paclitaxel. dCRT consisted of 50Gy with 
concurrent fluorouracil/cisplatin or 50.4Gy with concurrent 
carboplatin/paclitaxel. Overall survival (OS), disease-free 
survival (DFS) and locoregional control (LRC) were compared 
between older (>70 years) and younger patients (< 70 years). 
Cox models were used to obtain adjusted hazard ratios (HR) 
and 95% confidence intervals (CI). 
 
Results: The cohort consisted of 253 patients with a median 
follow up of 4.3 years. A group of 182 patients (72%) was < 70 
years (median age 60). The remaining 71 patients were >70 
years (median age 75). The two age groups (younger vs. 
older) differed significantly regarding smoking (59% vs. 31%; 
p<0.001), alcohol abuse (64% vs. 46%; p=0.007), Charlson 
comorbidity index (median 0 vs. 1; p=0.001) and weight loss 
prior to CRT (median 4 vs. 3 kgs; p=0.038). Most patients had 
stage IIA-IIIA disease (82%). Distribution of tumour stages was 
similar in the two age groups (stage IIA: 27% vs. 24%, stage 
IIB: 4% vs. 4%, stage IIIA: 51% vs. 55%).  
Initial treatment was nCRT with the intent to proceed to 
surgery in 169 patients, whereas 84 patients were planned 
for dCRT. Although surgery was the intent, 15% of the 
younger nCRT patients were not operated versus 35% of the 
older nCRT patients (p=0.01). Reasons to withhold surgery in 
the younger versus older patients were tumour progression 
(10% vs. 14%), toxicity (2% vs. 11%) or patient's own choice 
(3% vs. 11%), p=0.01. At baseline, there was a significant 
difference in the distribution of the final treatment given 
(nCRT + surgery, dCRT or nCRT without surgery; p<0.001).  
For the entire study population, OS at 3-years was 42%. In the 
multivariable analysis, no difference was found in OS 
between the two age groups (old vs. young; HR 0.72, 95% CI 
0.49–1.07, p=0.10). In the older age group, DFS (HR 0.66, 95% 
CI 0.45–0.98, p=0.04) and LRC (HR 0.43, 95% CI 0.23–0.82, 
p=0.01) were significantly better than in the younger age 
group. 
 
Conclusion: Elderly oesophageal cancer patients (>70 years) 
treated with neoadjuvant chemoradiotherapy followed by 
surgery or definitive chemoradiotherapy had long-term 
outcomes which did not differ from the outcomes of their 
younger counterparts. For oesophageal cancer patients, 
advanced age alone should not be a contraindication for 
chemoradiotherapy as a part of treatment with curative 
intent. 
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Purpose or Objective: Interobserver variation in target 
definition is a major contributor to geometric uncertainty in 
radiotherapy and consistent GTV delineation is crucial in dose 
escalation studies for oesophageal cancer. The routine use of 
FDG-PET for target delineation in oesophageal cancer 
patients treated with chemoradiation is debated in the 
literature. The aims of this study were to evaluate the 
interobserver variation of GTV delineation in The Netherlands 
and the impact of adding FDG-PET to CT images on 
interobserver variability in patients with oesophageal 
carcinoma. 
 
Material and Methods: Six cases were included from a 
prospective database of oesophageal carcinoma patients. All 
cases underwent a planning FDG-PET/CT scan in treatment 
position. Twenty upper gastro-intestinal dedicated radiation 
oncologists from 14 institutes in The Netherlands 
independently delineated the GTV first on CT, using 
additional clinical and diagnostic information. Secondly, they 
adjusted this GTV after CT and FDG-PET images were fused. 
As general metrics for interobserver variability, volumes and 
generalized conformity indices were calculated. For visual 
comparison of interobserver variation observer count maps 
were generated for each case, i.e. maps of voxels showing 
the number of enclosing observer delineations. To quantify 
the interobserver variation at the cranial and caudal border, 
the distance along the z-axis that contains 5-95% of the 
observers was used. 
 
Results: Significant differences in delineated GTV volumes 
were observed in 4 out of 6 cases after addition of FDG-PET 
to CT (Table 1). In 3 cases there was a significant volume 
reduction, whereas in one case a significant volume increase 
was found by PET, caused by unsuspected continuation of the 
tumour in the stomach. Generalized conformity indices were 
comparable for CT and FDG-PET/CT (Table 1). Count maps 
revealed that interobserver variation was mainly located at 
the cranial and caudal border (Figure 1A). The median 
observer variation was 26 mm (range 6-36 mm) at the cranial 
border and 18 mm (range 3-30 mm) at the caudal border 
(Figure 1B). Even after addition of PET interobserver 
variation remained more than 20 mm in 4 out of 6 cases 
(Figure 1B). In 2 cases a reduced interobserver variation was 
seen with PET/CT at the cranial border and in another 2 
cases only at the caudal border. An increased variation was 
seen with PET/CT compared with CT at the caudal border for 
the case with the unsuspected FDG uptake in the stomach. 
 
 
 
 
Conclusion: This nationwide Dutch contouring study in 
oesophageal cancer demonstrated that in daily clinical 
practice considerable GTV delineation variation is present, 
with variations up to 36 and 30 mm at the cranial and caudal 
border, respectively. Although FDG-PET significantly 
impacted the delineated volume in two-thirds of the 
patients, the addition of PET did not translate into an 
observer variation below 20 mm in 4 out of 6 cases. 
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